Also trades as: 0JW9.L (LSE) · $vol 0M
LITS NASDAQ
Lite Strategy, Inc.
1W: +6.7%
1M: +20.5%
3M: +50.0%
YTD: -27.9%
1Y: -63.8%
$1.11
+0.05 (+4.72%)
Weekly Expected Move ±8.3%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$37.8M
52W Range0.69-3.2
Volume278,063
Avg Volume335,585
Beta0.04
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOJustin J. File
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2003-12-18
Websitelitestrategy.com
9920 Pacific Heights Blvd.
San Diego, CA 92121
US
San Diego, CA 92121
US
858 369 7100
About Lite Strategy, Inc.
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Latest News
Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share
Lite Strategy Reports Fiscal 2026 Third Quarter Results
Lite Strategy Reports Fiscal 2026 Third Quarter Results
Lite Strategy Reports Fiscal 2026 Second Quarter Results
LiTHOS Announces Board and Management Change
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Flynn James P | P-Purchase | 25,000 | $0.86 | 2026-06-24 |
| File Justin J. | A-Award | 455,000 | $2.02 | 2026-02-12 |
| Flynn James P | P-Purchase | 70,000 | $1.40 | 2025-12-19 |
| Schornstein Alexande | S-Sale | 690,611 | $1.37 | 2025-12-18 |
| Flynn James P | P-Purchase | 12,100 | $1.88 | 2025-11-19 |